Sensible Medical Innovations

Executive Summary

Sensible Medical Innovations has developed the ReDS™ (Remote Dielectric Sensing) system, a non-invasive, 45-second bedside device that quantifies lung fluid volume in real time. By enabling early detection of pulmonary congestion, the system empowers clinicians to proactively manage heart failure patients, reducing hospital readmissions and supporting personalized care. With a commercial-stage product already on the market, the company addresses a critical unmet need in heart failure management—a condition responsible for high healthcare costs and frequent hospitalizations. The ReDS technology offers a unique advantage over traditional methods (e.g., daily weights or invasive monitoring) by providing accurate, actionable data in seconds, positioning Sensible Medical as a key player in the remote monitoring and digital health space. Given the growing prevalence of heart failure and the push for value-based care, Sensible Medical's platform has significant market potential. The company is well positioned to expand its commercial footprint through clinical evidence generation, regulatory approvals for new indications (e.g., outpatient or home use), and strategic partnerships with health systems. Sensible Medical's innovative approach to fluid management could transform standard of care, driving improvements in patient outcomes and cost savings. The conviction score reflects strong technology validation and commercial traction, balanced against competitive and adoption risks in a crowded med-tech landscape.

Upcoming Catalysts (preview)

• Q3 2026Publication of pivotal clinical trial results demonstrating reduction in heart failure readmissions80% success
• Q4 2026FDA clearance for expanded indication (e.g., outpatient or continuous monitoring)65% success
• Q2 2026Strategic partnership with a major hospital network or health system for large-scale deployment70% success